Ernexa Therapeutics Inc.
General ticker "ERNA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $139.3M (TTM average)
Ernexa Therapeutics Inc. does not follow the US Stock Market performance with the rate: -20.3%.
Estimated limits based on current volatility of 3.9%: low 1.22$, high 1.32$
Factors to consider:
- Total employees count: 9 as of 2022
- Current price 59.2% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.21$, 15.03$]
- 2025-12-31 to 2026-12-31 estimated range: [1.81$, 8.33$]
Financial Metrics affecting the ERNA estimates:
- Positive: with PPE of -0.5 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -14.11 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: Inventory ratio change, % of 73.64 > 0.84
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Negative: negative Industry operating income (median)
Short-term ERNA quotes
Long-term ERNA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.07MM | $0.58MM |
| Operating Expenses | $33.22MM | $21.20MM | $16.26MM |
| Operating Income | $-33.22MM | $-21.14MM | $-15.67MM |
| Non-Operating Income | $8.68MM | $-0.54MM | $-28.84MM |
| Interest Expense | $0.03MM | $0.61MM | $6.75MM |
| R&D Expense | $10.39MM | $5.92MM | $4.60MM |
| Income(Loss) | $-24.53MM | $-21.67MM | $-44.51MM |
| Taxes | $0.04MM | $-0.00MM | $0.03MM |
| Profit(Loss)* | $-24.58MM | $-21.67MM | $-44.54MM |
| Stockholders Equity | $12.11MM | $2.23MM | $1.70MM |
| Assets | $22.28MM | $49.13MM | $5.27MM |
| Operating Cash Flow | $-20.98MM | $-20.41MM | $-15.84MM |
| Capital expenditure | $0.30MM | $0.02MM | $0.37MM |
| Investing Cash Flow | $-0.05MM | $-0.02MM | $-0.36MM |
| Financing Cash Flow | $19.58MM | $16.56MM | $6.26MM |
| Earnings Per Share** | $-8.06 | $-4.08 | $-1.57 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.